Abstract | PURPOSE: MATERIALS AND METHODS: RESULTS: Local toxicity (grades 2 and 3 dysuria, and hematuria) was observed at doses of 8 mg/40 ml and above but 4 mg/40 ml was well tolerated with no systemic or local side effects. Apaziquone in urine increased linearly with the dose but no apaziquone was detected in plasma. In 8 of 12 patients complete macroscopic and histological disappearance of the marker lesion occurred. A correlation between response and NQO1 and/or glucose transporter 1 expression could not be established. CONCLUSIONS:
|
Authors | Rajiv Puri, Victor Palit, Paul M Loadman, Michael Flannigan, Tariq Shah, Guzanfar A Choudry, Saurajyoti Basu, John A Double, Gino Lenaz, Shanta Chawla, Mario Beer, Coen Van Kalken, Richard de Boer, Jos H Beijnen, Christopher J Twelves, Roger M Phillips |
Journal | The Journal of urology
(J Urol)
Vol. 176
Issue 4 Pt 1
Pg. 1344-8
(Oct 2006)
ISSN: 0022-5347 [Print] United States |
PMID | 16952628
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Aziridines
- Indolequinones
- apaziquone
|
Topics |
- Administration, Intravesical
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, pharmacokinetics)
- Aziridines
(administration & dosage, pharmacokinetics)
- Carcinoma, Transitional Cell
(drug therapy, pathology)
- Cohort Studies
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Indolequinones
(administration & dosage, pharmacokinetics)
- Male
- Middle Aged
- Pilot Projects
- Treatment Outcome
- Urinary Bladder Neoplasms
(drug therapy, pathology)
|